Recognition and treatment of neonatal community-associated MRSA pneumonia and bacteremia.
Community-associated strains of methicillin-resistant Staphylococcus aureus (CA-MRSA) have recently emerged as a major cause of serious infections among older children and are now being seen in NICU patients. We present the case of a preterm infant with CA-MRSA necrotizing pneumonia and secondary bacteremia.
Yee-Guardino
Stephanie
S
Department of Pediatrics, Section of Pediatric Infectious Diseases, Cleveland Clinic, 9500 Euclid Ave., Cleveland, Ohio 44195, USA.
Kumar
Deepak
D
Abughali
Nazha
N
Tuohy
Marion
M
Hall
Gerri S
GS
Kumar
Mary L
ML
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000188:drug therapy; D004334:Drug Administration Schedule; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D016106:Methicillin Resistance; D009336:Necrosis; D011023:Pneumonia, Staphylococcal / Q000175:diagnosis* / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects*; D014427:Twins; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D005839:Gentamicins; D014640:Vancomycin; D012293:Rifampin